Abstract:Although accounting for only 10% of all Parkinson’s disease (PD) cases, familial forms have contributed substantially to our understanding of its molecular pathophysiology. Among known autosomal-recessive forms of PD, several genes have been implicated in mitophagy, the process of degradation of dysfunctional mitochondria. The activation of the E3 ubiquitin ligase parkin (PARK2 [mendelian inheritance in man (MIM):602544]) is dependent on phosphatase and tensin homolog-induced kinase 1 (PINK1 [MIM: 608309]) and eventually leads to the mitophagy of reactive oxygen species (ROS)-producing mitochondria. Mutation of parkin and PINK1 in turn lead to the accumulation of ROS and dysfunctional mitochondria and ultimately cell damage and degeneration. DJ-1 (MIM:602533), among other roles, acts as a transcription factor influencing autophagy and mitochondrial dysfunction. Recently, Lesage and colleagues described homozygous and compound heterozygous mutations in vacuolar protein sorting 13C (VPS13C [MIM:608879]) as another monogenic, autosomal recessive cause of PD. The authors used a combination of whole-genome homozygosity linkage mapping in patients with confirmed consanguinity (inbreeding coefficient F 61⁄4 0) and 10-30x whole-exome sequencing and comparison to more than 500 healthy controls for gene identification. Clinically, the 3 identified subjects presented with an asymmetric bradykinetic-rigid syndrome with initially preserved Levodopa response but aggressive degenerative course and early cognitive decline similar to other recessive forms of PD. Postmortem analysis of 1 case revealed combined Lewy body and TAU pathology. Subsequent cell culture experiments on human HEK293T and nonhuman primate COS-7 cells verified the location of VSP13C on the mitochondrial surface and demonstrated its influence on mitochondrial activity and maintenance as well as multiple interdependent loops between parkin, PINK1, and VPS13C in the regulation of mitophagy. The involvement of vacuolar protein sorting family proteins in vesicular trafficking suggests that VSP13C might be involved in peroxisomal transport. Observational and experimental data in animal models and humans on the effect of MPTP, rotenone, and paraquat has long suggested a causal relationship between complex I inhibition and PD. Similarly, axonal dystrophy in PLA2G6 has recently been attributed to mitochondrial dysfunction. Strengthened by prior genetic work in familial PD, the discovery of VPS13C continues a long line of evidence that links 2 fundamental cell functions in the pathophysiology of PD: energy metabolism and degradation of dysfunctional cell organelles. At the same time, it further strengthens the role of PINK1/parkin-dependent regulation of mitophagy.

VPS35 or retromer as a potential target for neurodegenerative disorders: barriers to progress

Exploring the triad: VPS35, neurogenesis, and neurodegenerative diseases

Research Progress on Vesicular Trafficking in Amyotrophic Lateral Sclerosis.

VPS35 and retromer dysfunction in Parkinson's disease

VPS35-deficiency Results in an Impaired AMPA Receptor Trafficking and Decreased Dendritic Spine Maturation

VPS35 Interacts with Dopamine Transportor and Disrupts Dopamine Transporter Recycling Pathway

VPS35 Haploinsufficiency Increases Alzheimer’s Disease Neuropathology

Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient-Derived Neurons

Expression of Low Level of VPS35-mCherry Fusion Protein Diminishes Vps35 Depletion Induced Neuron Terminal Differentiation Deficits and Neurodegenerative Pathology, and Prevents Neonatal Death

Retromer dysfunction in amyotrophic lateral sclerosis

Enhancing Retromer Complex Stability Ameliorates Synaptic Dysfunction in a Mouse Model of Alzheimer's Disease

The crucial role of VPS35 and SHH in Parkinson's disease: Understanding the mechanisms behind the neurodegenerative disorder

VPS13C—Another Hint at Mitochondrial Dysfunction in Familial Parkinson's Disease

Retromer-dependent lysosomal stress in Parkinson's disease

Vps35 Regulates Cell Surface Recycling and Signaling of Dopamine Receptor D1

Microglial VPS35 Deficiency Impairs Aβ Phagocytosis and Aβ-induced Disease-Associated Microglia, and Enhances Aβ Associated Pathology.

Mutant D620N and VPS35 induces motor dysfunction and impairs DAT-mediated dopamine recycling pathway

Mutant VPS35-D620N Induces Motor Dysfunction and Impairs DAT-mediated Dopamine Recycling Pathway.

Emergent glutamate & dopamine dysfunction in VPS35(D620N) knock-in mice and rapid reversal by LRRK2 inhibition

V-ATPase Dysfunction in the Brain: Genetic Insights and Therapeutic Opportunities

Targeting VPS34 in autophagy: An update on pharmacological small-molecule compounds